CD47 and cancer: Consequently, a strong enhanced antitumor effect of SG635‐SF was proved in vivo and the enhanced antitumor effect of SG635‐SF was CD47‐dependent, suggesting the potency of SG635‐SF in the treatment of CD47‐positive cancer.